The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

MIA  -  melanoma inhibitory activity

Homo sapiens

Synonyms: CD-RAP, Melanoma inhibitory activity protein, Melanoma-derived growth regulatory protein
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MIA


Psychiatry related information on MIA

  • Although the combined impact of MIA complications seems to determine the extremely poor clinical outcome in the ESRD patients, there are significant unexplained individual differences in the development of the MIA syndrome, implying that genetic differences might play a role [5].

High impact information on MIA

  • Positivity for MIA (i.e., immunohistologic staining by MIA-15-5, which defines H/Le(y)/Le(b) antigens) is inversely correlated with survival among patients with primary lung cancer and may be of prognostic value [6].
  • The growth-inhibiting peptide hormone somatostatin stimulates phosphotyrosine phosphatase activity in the human pancreatic cell line MIA PaCa-2 [7].
  • Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2) [8].
  • The exposure of MIA PaCa-2 cells to 1.6 X 10(-5) M 5-fluorouracil (FUra) followed by 2 X 10(-8) M DHAD or 3 X 10(-7) M ADR had an additive (with DHAD) or synergistic (with ADR) effect when the two drugs were given simultaneously and a synergistic effect with either drug when they were given 2, 6, or 24 hours apart [8].
  • METHODS: We measured apoptosis and necrosis, caspase activation, and mitochondrial dysfunction in MIA PaCa-2 and PANC-1 pancreatic carcinoma cells both detached and attached to ECM proteins [9].

Chemical compound and disease context of MIA


Biological context of MIA


Anatomical context of MIA


Associations of MIA with chemical compounds


Physical interactions of MIA

  • MIA is a potent melanoma detachment factor that interferes with cellular adherence by binding to fibronectin and laminin, blocking their interaction with alpha4beta1 and alpha5beta1 integrins [24].

Regulatory relationships of MIA


Other interactions of MIA

  • Only modest changes of CRP, sIL-6R, sTNFRII and MIA occurred during the run [29].
  • Thus, our data suggest that COMP and MIA are markers for distinct aspects of joint metabolism and/or damage in both disease and sport [29].
  • RESULTS: Compared with healthy controls, the runner's baseline serum levels of TNF-alpha, sIL-6R, COMP and MIA were significantly increased [29].
  • Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype [15].
  • Of these rheumatic diseases, a significant increase in MIA serum concentrations was seen only in patients with RA, associated with rheumatoid factor (RF) positivity and joint destruction [3].

Analytical, diagnostic and therapeutic context of MIA


  1. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. Stoll, R., Renner, C., Zweckstetter, M., Brüggert, M., Ambrosius, D., Palme, S., Engh, R.A., Golob, M., Breibach, I., Buettner, R., Voelter, W., Holak, T.A., Bosserhoff, A.K. EMBO J. (2001) [Pubmed]
  2. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Bosserhoff, A.K., Buettner, R. Histol. Histopathol. (2002) [Pubmed]
  3. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Müller-Ladner, U., Bosserhoff, A.K., Dreher, K., Hein, R., Neidhart, M., Gay, S., Schölmerich, J., Buettner, R., Lang, B. Rheumatology (Oxford, England) (1999) [Pubmed]
  4. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Blesch, A., Bosserhoff, A.K., Apfel, R., Behl, C., Hessdoerfer, B., Schmitt, A., Jachimczak, P., Lottspeich, F., Buettner, R., Bogdahn, U. Cancer Res. (1994) [Pubmed]
  5. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Pecoits-Filho, R., Nordfors, L., Lindholm, B., Hoff, C.M., Schalling, M., Stenvinkel, P. Kidney Int. Suppl. (2003) [Pubmed]
  6. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. Miyake, M., Taki, T., Hitomi, S., Hakomori, S. N. Engl. J. Med. (1992) [Pubmed]
  7. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Pan, M.G., Florio, T., Stork, P.J. Science (1992) [Pubmed]
  8. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2). Fountzilas, G., Gratzner, H., Lim, L.O., Yunis, A.A. J. Natl. Cancer Inst. (1986) [Pubmed]
  9. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. Vaquero, E.C., Edderkaoui, M., Nam, K.J., Gukovsky, I., Pandol, S.J., Gukovskaya, A.S. Gastroenterology (2003) [Pubmed]
  10. Regulation of Integrin Activity by MIA. Bauer, R., Humphries, M., Fässler, R., Winklmeier, A., Craig, S.E., Bosserhoff, A.K. J. Biol. Chem. (2006) [Pubmed]
  11. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Miyamoto, H., Murakami, T., Tsuchida, K., Sugino, H., Miyake, H., Tashiro, S. Pancreas (2004) [Pubmed]
  12. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Lee, M.T., Liebow, C., Kamer, A.R., Schally, A.V. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  13. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cullen, J.J., Hinkhouse, M.M., Grady, M., Gaut, A.W., Liu, J., Zhang, Y.P., Weydert, C.J., Domann, F.E., Oberley, L.W. Cancer Res. (2003) [Pubmed]
  14. Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Venkatasubbarao, K., Ammanamanchi, S., Brattain, M.G., Mimari, D., Freeman, J.W. Cancer Res. (2001) [Pubmed]
  15. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Poser, I., Golob, M., Buettner, R., Bosserhoff, A.K. Mol. Cell. Biol. (2003) [Pubmed]
  16. Functional role of MIA in melanocytes and early development of melanoma. Poser, I., Tatzel, J., Kuphal, S., Bosserhoff, A.K. Oncogene (2004) [Pubmed]
  17. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Jachimczak, P., Apfel, R., Bosserhoff, A.K., Fabel, K., Hau, P., Tschertner, I., Wise, P., Schlingensiepen, K.H., Schuler-Thurner, B., Bogdahn, U. Int. J. Cancer (2005) [Pubmed]
  18. Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. Bosserhoff, A.K., Moser, M., Schölmerich, J., Buettner, R., Hellerbrand, C. J. Biol. Chem. (2003) [Pubmed]
  19. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Lougheed, J.C., Holton, J.M., Alber, T., Bazan, J.F., Handel, T.M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  20. Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. Bianco, C., Giovannetti, E., Ciardiello, F., Mey, V., Nannizzi, S., Tortora, G., Troiani, T., Pasqualetti, F., Eckhardt, G., de Liguoro, M., Ricciardi, S., Del Tacca, M., Raben, D., Cionini, L., Danesi, R. Clin. Cancer Res. (2006) [Pubmed]
  21. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. Bosserhoff, A.K., Moser, M., Hein, R., Landthaler, M., Buettner, R. J. Pathol. (1999) [Pubmed]
  22. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)? Deichmann, M., Benner, A., Kuner, N., Wacker, J., Waldmann, V., Näher, H. Melanoma Res. (2001) [Pubmed]
  23. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Lian, J.P., Word, B., Taylor, S., Hammons, G.J., Lyn-Cook, B.D. Anticancer Res. (2004) [Pubmed]
  24. Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma. Marr, D.G., Poser, I., Shellman, Y.G., Bosserhoff, A.K., Norris, D.A. Int. J. Oncol. (2004) [Pubmed]
  25. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. DeArmond, D., Brattain, M.G., Jessup, J.M., Kreisberg, J., Malik, S., Zhao, S., Freeman, J.W. Oncogene (2003) [Pubmed]
  26. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. Deichmann, M., Benner, A., Bock, M., Jäckel, A., Uhl, K., Waldmann, V., Näher, H. J. Clin. Oncol. (1999) [Pubmed]
  27. Molecular cloning and characterization of OSR1 on human chromosome 2p24. Katoh, M. Int. J. Mol. Med. (2002) [Pubmed]
  28. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Leung, H.Y., Gullick, W.J., Lemoine, N.R. Int. J. Cancer (1994) [Pubmed]
  29. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Neidhart, M., Müller-Ladner, U., Frey, W., Bosserhoff, A.K., Colombani, P.C., Frey-Rindova, P., Hummel, K.M., Gay, R.E., Häuselmann, H., Gay, S. Osteoarthr. Cartil. (2000) [Pubmed]
  30. Characterization and expression pattern of the novel MIA homolog TANGO. Bosserhoff, A.K., Moser, M., Buettner, R. Gene Expr. Patterns (2004) [Pubmed]
  31. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Bosserhoff, A.K., Kaufmann, M., Kaluza, B., Bartke, I., Zirngibl, H., Hein, R., Stolz, W., Buettner, R. Cancer Res. (1997) [Pubmed]
WikiGenes - Universities